The efficacy of montelukast and airway mast cell profiles in patients with cough variant asthma

Journal of Asthma

Volumn 45, Issue 3, 2008, Pages 243-250

  Kawai, Seiko ^a   Baba, Kenji ^a   Matsubara, Ayako ^a   Shiono, Hiroyuki ^a   Okada, Tadashi ^a   Yamaguchi, Etsuro ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD63; Chronic cough; Cough variant asthma; Cysteinyl leukotriene receptor antagonist; Leukotriene; Mast cell; Montelukast

Indexed keywords

CD63 ANTIGEN; FLUTICASONE PROPIONATE; MONTELUKAST; TRYPTASE INHIBITOR;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHUS BIOPSY; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; COUGH VARIANT ASTHMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBEROPTIC BRONCHOSCOPY; GENERAL CONDITION IMPROVEMENT; HUMAN; HUMAN CELL; MALE; MAST CELL; MEDICAL ASSESSMENT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ACETATES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BASOPHILS; COUGH; EOSINOPHILS; FEMALE; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; MALE; MAST CELLS; MIDDLE AGED; QUINOLINES; RESPIRATORY MUCOSA; TREATMENT OUTCOME;

EID: 42249088238     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900801888863     Document Type: Article

References (33)

1. Global strategy for asthma management and prevention 2003. New York: National Institutes of Health, 2003: 115-119.
2. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast -cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346: 1699-1705.
3. Henderson WR Jr. Eicosanoids and lung inflammation. Am Rev Respir Dis 1987; 135: 1176-1185.
4. Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev 1988; 40: 49-84.
5. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484-486.
6. Jones TR, Davies C, Daniel EE. Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle. Can J Physiol Pharmacol 1982; 60: 638-643.
7. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998; 19: 453-461.
8. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, Adachi M. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732-738.
9. Persson CG. Role of plasma exudation in asthmatic airways. Lancet 1986; 2: 1126-1129.
10. Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting manifestation of bronchial asthma. New Engl J Med 1979; 300: 633-637.
11. Braman SS, Corrao WM. Chronic cough diagnosis and treatment. Primary Care 1958; 12: 217-225.
12. Koh YY, Jeong JH, Park Y, Kim CK. Development of wheezing in patients with cough variant asthma during an increase in airway responsiveness. Eur Respir J 1999; 14: 302-308.
13. Iwanaga T, Inuzuka S, Takahashi N, Kishikawa R, Yokota K, Ikeda T, Hirose T, Tsurutani H, Nishima S. Cough variant asthma among patients with chronic persistent cough and its clinical outcome. Arerugi 1998; 47: 457-461.
14. Puolijoki H, Lahdensuo A. Chronic cough as a risk indicator of bronchopulmonary disease. Eur J Respir Dis 1987; 71: 77-85.
15. Makino S, Ikemori R, Fukuda T, Motojima S, Namai S, Toda M, Yamai T, Yamada G, Yukawa T. Clinical evaluation of standard method of acetylcholine inhalation test in bronchial asthma. Arerugi 1984; 33: 167-175. [Article in Japanese.]
16. British Thoracic Society Bronchoscopy Guidelines Committee: British Thoracic Society Guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56 (suppl I): i1-i21.
17. Niimi A, Matsumoto H, Minakuchi M, Masanori K. Ryoichi A. Airway remodeling in patients with cough variant asthma. Lancet 2000; 356: 564-565.
18. Knol EF, Hoogerwerf M, Mul FPJ, Kujipers TW, Roos D. Analysis using the myeloid panel mAb of purified basophils obtained from human blood: changes in expression during degranulation. Schlossman S F, et al., eds. Leucocyte Typing V. New York : Oxford University Press, 1995: 1049-1051.
19. Krauth MT, Majlesi Y, Florian S, Bohm A, Hauswirth AW, Ghannadan M, Wimazal F, Raederer M, Wrba F, Valent P. Cell surface membrane antigen phenotype of human gastrointestinal mast cells. Int Arch Allergy Immunol 2005; 138: 111-120.
20. Grützkan A, Smorodchenko A, Lippert U, Kirchhof, Artuc M, Henz BM. LAMP-1 and LAMP-2, but not LAMP-3 are reliable markers for activation-induced secretion of human mast cells. Cytometry Part A 2004; 31A: 62-68.
21. Furumo T, Teshima R, Kitani S, Sawada J, Nakanishi M. Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Biochem Biphys Res Commun 1996; 219: 740-744.
22. Valent P, Schernthaner G-H, Sperr WR, Fritsch G, Agis H, Wilheim M, Burring HJ, Orfao A, Escribano L. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001; 179: 74-81.
23. Kraft S, Fleming T, Billingsley JM, Lin S-Y, Jouvin M-H, Storz P, Kinet JP Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. J Exp Med 2005: 201; 385-396.
24. Yasuda M, Hasunuma Y, Adachi H, Sekine C, Sakanishi T, Hashimoto H,. Yagita CRaH Okumura K. Expression and function of fibronectin binding integrins on rat mast cells. Int. Immunol 1995; 7: 251-258.
25. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, Adachi M. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732-738.
26. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835-841.
27. Widdicombe JG. Neurophysiology of the cough reflex. Eur Respir J 1995; 8: 1193-1202.
28. Lee SY, Kim MK, Shin C, Shim JJ, Kim HK, Kang KH, Yoo SH, In KH. Substance P-Immunoreactive nerves in endobronchial biopsies in cough-variant asthma and classic asthma. Respiration 2003; 70: 49-53.
29. McAlexander MA, Myers AC, Undem BJ. Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway. J Pharmacol Exp Ther 1998; 285: 602-607.
30. Ellis JL, Undem BJ. Role of peptidoleukotrienes in capsaicine-sensitive sensory fiber-mediated responses in guinea-pig airways. J Physiol 1991; 436: 469-484.
31. Kawana S, Liang Z, Nagano M, Suzuki H. Role of substance P in stress-derived degranulation of dermal mast cells in mice. J Dermatol Sci 2006; 42: 47-54.
32. T type of human lung mast cell. J Allergy Clin Immunol 2005; 115: 1162-1168.
33. Bloomquist EI, Kream RM. Leukotriene D4 acts in part to contract guinea pig ileum smooth muscle by releasing substance P. J Pharmacol Exp Ther 1987; 240: 523-528.